Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Commentary|Articles|June 18, 2025
Hematologists Highlight Notable Insights From the 2025 EHA Congress
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.
Advertisement
Advertisement
The
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
The top 5 OncLive TV videos of the week.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Advertisement
Advertisement